ID

31074

Description

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE); ODM derived from: https://clinicaltrials.gov/show/NCT00719472

Link

https://clinicaltrials.gov/show/NCT00719472

Keywords

Versions (1)
  1. 7/18/18 7/18/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 18, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Hodgkin's Lymphoma NCT00719472

English

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
age ≥ 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
Description

Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled

Data type

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0393022
UMLS CUI [2,2]
C0332287
UMLS CUI [2,3]
C0163868
UMLS CUI [2,4]
C0205539
UMLS CUI [3]
C0013089
UMLS CUI [4]
C0085752
UMLS CUI [5]
C0591904
UMLS CUI [6]
C0042679
UMLS CUI [7]
C0032952
UMLS CUI [8]
C0032950
UMLS CUI [9,1]
C0024301
UMLS CUI [9,2]
C0332155
UMLS CUI [10,1]
C0393022
UMLS CUI [10,2]
C0332287
UMLS CUI [10,3]
C0056633
UMLS CUI [10,4]
C0205539
eastern cooperative oncology group (ecog) performance status 0-2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
Description

Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification

Data type

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C1868885
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5,1]
C0018802
UMLS CUI [5,2]
C1275491
UMLS CUI [6,1]
C0085612
UMLS CUI [6,2]
C1514873
UMLS CUI [6,3]
C0013227
UMLS CUI [7,1]
C0085096
UMLS CUI [7,2]
C1275491
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
Description

Criteria Fulfill | Study Subject Participation Status Excluded

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
UMLS CUI [2,1]
C2348568
UMLS CUI [2,2]
C0332196
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
Description

Circulating Lymphocyte Count

Data type

boolean

Alias
UMLS CUI [1,1]
C0175630
UMLS CUI [1,2]
C0200635
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
Description

Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion

Data type

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0205404
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C1516728
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0393022
UMLS CUI [3,3]
C0574032
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
Description

Premedication Adrenal Cortex Hormones Additional | Exception Prednisone

Data type

boolean

Alias
UMLS CUI [1,1]
C0033045
UMLS CUI [1,2]
C0001617
UMLS CUI [1,3]
C1524062
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0032952
Back to the top of the page

Similar models

Eligibility Non-Hodgkin's Lymphoma NCT00719472

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
age ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Diffuse Large B-Cell Lymphoma untreated | Rituximab plus CHOP Scheduled | Doxorubicin | Adriamycin | Oncovin | Vincristine | Prednisone | Prednisolone | Follicular Lymphoma untreated | Rituximab plus CVP Scheduled
Item
patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m^2 plus chop (cyclophosphamide, hydroxydaunorubicin [also called doxorubicin or adriamycin], oncovin [vincristine], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy
boolean
C0079744 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0393022 (UMLS CUI [2,1])
C0332287 (UMLS CUI [2,2])
C0163868 (UMLS CUI [2,3])
C0205539 (UMLS CUI [2,4])
C0013089 (UMLS CUI [3])
C0085752 (UMLS CUI [4])
C0591904 (UMLS CUI [5])
C0042679 (UMLS CUI [6])
C0032952 (UMLS CUI [7])
C0032950 (UMLS CUI [8])
C0024301 (UMLS CUI [9,1])
C0332155 (UMLS CUI [9,2])
C0393022 (UMLS CUI [10,1])
C0332287 (UMLS CUI [10,2])
C0056633 (UMLS CUI [10,3])
C0205539 (UMLS CUI [10,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cardiovascular Disease | Uncontrolled hypertension | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Ventricular arrhythmia Requirement Pharmaceutical Preparations | Peripheral Vascular Disease New York Heart Association Classification
Item
* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment)
boolean
C0007222 (UMLS CUI [1])
C1868885 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0018802 (UMLS CUI [5,1])
C1275491 (UMLS CUI [5,2])
C0085612 (UMLS CUI [6,1])
C1514873 (UMLS CUI [6,2])
C0013227 (UMLS CUI [6,3])
C0085096 (UMLS CUI [7,1])
C1275491 (UMLS CUI [7,2])
Criteria Fulfill | Study Subject Participation Status Excluded
Item
patients who meet any of the following criteria will be excluded from further study participation after cycle 1:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2,1])
C0332196 (UMLS CUI [2,2])
Circulating Lymphocyte Count
Item
circulating lymphocyte count > 5,000/μl before the cycle 2 rituximab infusion
boolean
C0175630 (UMLS CUI [1,1])
C0200635 (UMLS CUI [1,2])
Adverse event Serious | Adverse event CTCAE Grades | Relationship Rituximab Infusion
Item
development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion
boolean
C0877248 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
C0439849 (UMLS CUI [3,1])
C0393022 (UMLS CUI [3,2])
C0574032 (UMLS CUI [3,3])
Premedication Adrenal Cortex Hormones Additional | Exception Prednisone
Item
prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens
boolean
C0033045 (UMLS CUI [1,1])
C0001617 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0032952 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial